TNF and autoimmune disease: In spite of earlier alarming data [50], there is currently no evidence of an increased incidence of malignancy among patients exposed to TNF inhibitors compared with MTX [36], and the increased risk of malignancy has been attributed to the autoimmune disease itself, rather than to treatment with TNF inhibitors [51–53].